# Sulfated Pelvetia siliquosa Polysaccharides Attenuate Pyroptosis via NF-κB Pathway Inhibition Against Calcium Oxalate Stone Formation

**Authors:** Xin-Yi Tong, Xue-Wu Chen, Jia-Yi Zhang, Jian-Ming Ouyang

PMC · DOI: 10.3390/md24020072 · 2026-02-08

## TL;DR

This study shows that sulfated polysaccharides from Pelvetia siliquosa reduce kidney stone formation by inhibiting cell death and inflammation.

## Contribution

The novel finding is that sulfated Pelvetia siliquosa polysaccharides inhibit pyroptosis and NF-κB pathways to prevent calcium oxalate stone formation.

## Key findings

- Sulfated polysaccharides reduced pyroptosis in HK-2 cells by up to 6.35%.
- PSP3 showed higher protection efficiency than PSP0 due to increased sulfation.
- Polysaccharides inhibited NLRP3/ASC/caspase-1/IL-1β pathways and reduced crystal adhesion.

## Abstract

Objective: The formation of calcium oxalate (CaOx) kidney stones is accompanied by the pyroptosis of renal epithelial cells. The risk of kidney stone formation can possibly be reduced through pyroptosis inhibition. Methods: Pyroptosis of HK-2 cells induced by 3 µm CaOx monohydrate (COM-3 µm) was inhibited by Pelvetia siliquosa polysaccharides before and after sulfation (PSP0 and PSP3, with −OSO3− contents of 1.04% and 36.12%, respectively). The inhibitory efficiency and mechanism of PSP0 and PSP3 were evaluated via caspase-1/PI double staining and Western blot detection of pathway proteins in pyroptosis cells. The potential anti-stone effect of polysaccharides was evaluated through measurement of the extent of crystal adhesion on the cell surface. Results: The proportion of pyroptosis cells induced by COM-3 µm reached 17.87%. After protection by PSP0 and PSP3, the percentage of pyroptosis cells was reduced to 12.7% and 6.35%. The levels of NLRP3, ASC, gasdermin D, IL-1β, and IL-18 related to pyroptosis were downregulated. In addition, the activation of the NF-κB pathway was considerably inhibited. During inhibition of pyroptosis, reactive oxygen species and lactate dehydrogenase levels were decreased, the integrity of zonula occludens-1 protein was restored, and the expressions of CaOx-specific adhesion proteins (ANXA3 and CD44) were substantially decreased. As a result, the adhesion of COM crystals on the cell surface was reduced. PSP3 exhibited a higher protection energy efficiency than PSP0. Conclusions: PSP0 and PSP3 inhibited the pyroptosis of HK-2 cells through the NLRP3/ASC/caspase-1/IL-1β pathway, which caused the inhibition of cell inflammation and injury, reduced the expressions of adhesion proteins, and reduced the risk of CaOx crystal adhesion and stone formation. The biological activity of PSP0 and PSP3 after sulfation modification increased.

## Linked entities

- **Genes:** NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], STS (steroid sulfatase) [NCBI Gene 412], IL1B (interleukin 1 beta) [NCBI Gene 3553], IL18 (interleukin 18) [NCBI Gene 3606], ANXA3 (annexin A3) [NCBI Gene 306], CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960]
- **Chemicals:** calcium oxalate (PubChem CID 33005)

## Full-text entities

- **Genes:** Pspn (persephin) [NCBI Gene 19197] {aka PSP}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, Hmgb1 (high mobility group box 1) [NCBI Gene 15289] {aka HMG-1, Hmg1, SBP-1, p30}, Spp1 (secreted phosphoprotein 1) [NCBI Gene 20750] {aka 2AR, Apl-1, BNSP, BSPI, Bsp, ETA-1}, Casp1 (caspase 1) [NCBI Gene 12362] {aka ICE, Il1bc}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, Anxa1 (annexin A1) [NCBI Gene 16952] {aka Anx-1, Anx-A1, C430014K04Rik, Lpc-1, Lpc1}, Lbp (lipopolysaccharide binding protein) [NCBI Gene 16803] {aka Bpifd2, Ly88}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, PYCARD (PYD and CARD domain containing) [NCBI Gene 29108] {aka ASC, CARD5, TMS, TMS-1, TMS1}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, CD44 (CD44 molecule) [NCBI Gene 395666], Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, Anxa3 (annexin A3) [NCBI Gene 11745] {aka Anx3}, Anxa2 (annexin A2) [NCBI Gene 12306] {aka Cal1h, PAP-IV, p36}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, GSDMD (gasdermin D) [NCBI Gene 79792] {aka DF5L, DFNA5L, FKSG10, GSDMDC1}, Gsdmd (gasdermin D) [NCBI Gene 69146] {aka 1810036L03Rik, DF5L, Dfna5l, GsdmD-1, Gsdmdc1, M2-4}, Il18 (interleukin 18) [NCBI Gene 16173] {aka Igif, Il-18}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], Pycard (PYD and CARD domain containing) [NCBI Gene 66824] {aka 9130417A21Rik, Asc, CARD5, TMS-1, TNS1, masc}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Fgf1 (fibroblast growth factor 1) [NCBI Gene 14164] {aka Dffrx, Fam, Fgf-1, Fgf2b, Fgfa}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, ANXA3 (annexin A3) [NCBI Gene 306] {aka ANX3}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}
- **Diseases:** cardiac injury (MESH:D006331), liver injury (MESH:D017093), kidney inflammation (MESH:D007674), inflammatory bowel disease (MESH:D015212), DC (MESH:D007174), neuronal damage (MESH:D009410), sepsis (MESH:D018805), necrosis (MESH:D009336), atherosclerosis (MESH:D050197), leukemia (MESH:D007938), colorectal cancer (MESH:D015179), reperfusion injury (MESH:D015427), arthritis (MESH:D001168), urolithiasis (MESH:D052878), toxicity (MESH:D064420), bone destruction (MESH:D001847), calcium kidney stone (MESH:D007669), colitis (MESH:D003092), gastrointestinal adverse (MESH:D005767), myocardial ischemia (MESH:D017202), neurocognitive impairment (MESH:D019965), COM (MESH:C563477), obesity (MESH:D009765), gastric cancer (MESH:D013274), cartilage injury (MESH:D002357), Stone Formation (MESH:D058426), acute respiratory distress syndrome (MESH:D012128), arthritic (MESH:D015535), mitochondrial damage (MESH:D028361), Parkinson's disease (MESH:D010300), cervical cancer (MESH:D002583), nephrolithiasis (MESH:D053040), cardiac inflammation (MESH:D007249), gouty nephropathy (MESH:C537696), injury to (MESH:D014947), lung injury (MESH:D055370), tumor (MESH:D009369), lung cancer (MESH:D008175), Alzheimer's disease (MESH:D000544)
- **Chemicals:** Alkali (MESH:D000468), lipid (MESH:D008055), paraformaldehyde (MESH:C003043), LPS (MESH:D008070), citrate (MESH:D019343), CO2 (MESH:D002245), Vitexin (MESH:C032731), sulfuric acid (MESH:C033158), Ca (MESH:D002118), ROS (MESH:D017382), HNO3 (MESH:D017942), 4,6-diamidino-2-phenylindole (MESH:C007293), L-Fucose (MESH:D005643), HClO4 (MESH:C576518), Tween 20 (MESH:D011136), indapamide (MESH:D007190), glutaraldehyde (MESH:D005976), penicillin (MESH:D010406), BAY 11-7082 (MESH:C434003), pyridine (MESH:C023666), Na2C2O4 (MESH:D019815), COM-3 (-), propidium iodide (MESH:D011419), malondialdehyde (MESH:D008315), Hoechst 33342 (MESH:C017807), hydrochlorothiazide (MESH:D006852), 2',7' -dichlorofluorescein diacetate (MESH:C029569), COM (MESH:D002129), potassium citrate (MESH:D019357), water (MESH:D014867), CCK-8 (MESH:D012844), thiazide (MESH:D049971), ethanol (MESH:D000431), sulfur trioxide (MESH:C011118), SDS (MESH:D012967), CaCl2 (MESH:D002122), sulfate (MESH:D013431), Allopurinol (MESH:D000493), Phosphate (MESH:D010710), chlorthalidone (MESH:D002752), PI (MESH:D010716), PS (MESH:D010758), gold (MESH:D006046), punicalagin (MESH:C115642), streptomycin (MESH:D013307), VX-765 (MESH:C520022), Triton X-100 (MESH:D017830), monosaccharide (MESH:D009005), oxalate (MESH:D010070), Polysaccharide (MESH:D011134), FITC (MESH:D016650)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Ovis aries (domestic sheep, species) [taxon 9940], Allium sativum (garlic, species) [taxon 4682], Rheum palmatum (species) [taxon 137221], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** retinal pigment epithelia-19 — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0145), MH-S — Mus musculus (Mouse), Transformed cell line (CVCL_3855), CCK-8 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_2873)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941881/full.md

---
Source: https://tomesphere.com/paper/PMC12941881